Success Metrics

Clinical Success Rate

100.0%

Based on 1 completed trials

Completion Rate

100%(1/1)

Active Trials

4(80%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_2

80%

Ph phase_1

20%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

1(20.0%)

Phase 2Efficacy & side effects

4(80.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(4)

Completed(1)

Detailed Status

Recruiting4

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 11 (20.0%)

Phase 24 (80.0%)

Trials by Status

recruiting480%

completed120%

Recent Activity

4 active trials

Showing 5 of 5

recruitingphase_1

5G-PEARL: Paxalisib in Malignant Brain Tumours

NCT07391215

recruitingphase_2

Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

NCT06739395

recruitingphase_2

Metronomic Temozolomide in Unfit NENs Patients Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): MeTe Study

NCT05554003

recruitingphase_2

The Efficacy and Safety of Temozolomide in SDH-deficient GIST

NCT05661643

completedphase_2

The Efficacy and Safety of Temozolomide in Patients With MPPGL

NCT05858177

Clinical Trials (5)

Showing 5 of 5 trials

NCT07391215Phase 1

5G-PEARL: Paxalisib in Malignant Brain Tumours

Recruiting

NCT06739395Phase 2

Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

Recruiting

NCT05554003Phase 2

Metronomic Temozolomide in Unfit NENs Patients Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): MeTe Study

Recruiting

NCT05661643Phase 2

The Efficacy and Safety of Temozolomide in SDH-deficient GIST

Recruiting

NCT05858177Phase 2

The Efficacy and Safety of Temozolomide in Patients With MPPGL

Completed

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5